Progyny, Inc. (NASDAQ:PGNY) CEO David J. Schlanger sold 1,004 shares of Progyny stock in a transaction dated Thursday, April 1st. The shares were sold at an average price of $46.19, for a total transaction of $46,374.76. Following the transaction, the chief executive officer now directly owns 1,004 shares of the company’s stock, valued at $46,374.76. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
PGNY opened at $44.87 on Thursday. The stock has a market capitalization of $3.91 billion, a PE ratio of 407.91 and a beta of 1.83. Progyny, Inc. has a 1-year low of $17.90 and a 1-year high of $53.48. The firm has a 50-day moving average price of $46.21 and a two-hundred day moving average price of $39.10.
Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Wednesday, February 24th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.06 by $0.01. Progyny had a net margin of 1.03% and a return on equity of 7.43%. The company had revenue of $100.30 million during the quarter. On average, sell-side analysts expect that Progyny, Inc. will post 0.14 EPS for the current fiscal year.
PGNY has been the subject of several analyst reports. Bank of America raised shares of Progyny from a “neutral” rating to a “buy” rating in a report on Tuesday, March 16th. Zacks Investment Research downgraded shares of Progyny from a “hold” rating to a “sell” rating in a report on Saturday, February 27th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $37.71.
Progyny Company Profile
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Featured Article: What is insider trading?
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.